KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Genomic analysis of Salmonella Typhi from a typhoid conjugate vaccine trial.

Belson M Kutambe, Priyanka D Patel, Kenneth Chizani, Niza Silungwe, Christopher Kukacha, Megan E Carey, James E Meiring, Matthew B Laurens, Melita A Gordon, Philip M Ashton

Microb Genom 12(5) 001721

PMID42149110
PMCIDPMC13183295
DOI10.1099/mgen.0.001721
发表日期2026-05-18
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig. 1.:图注未提示 KM 曲线;Fig. 2.:图注未提示 KM 曲线;Fig. 3.:图注未提示 KM 曲线;Fig. 4.:图注未提示 KM 曲线。
摘要

摘要

Background. Salmonella enterica serovar Typhi (S. Typhi), the causative agent of typhoid fever, continues to pose a major public health challenge in many low- and middle-income countries. The World Health Organization recommended typhoid conjugate vaccine (TCV) use in countries with a high burden of disease and/or high rates of antimicrobial resistance (AMR). Recent introductions of TCVs into national immunization programmes are expected to substantially reduce this burden. However, the impact of vaccine introduction on pathogen populations has not been widely investigated.Methods. To fill this research gap, we analysed the genomes of isolates from a trial in Malawi. A Phase 3, double-blind, randomized, controlled trial enrolled 28,130 healthy children aged 9 months through 12 years of age to receive either TCV (Typbar-TCV, Bharat Biotech) or meningococcal A conjugate vaccine (MenA). We conducted Illumina whole-genome sequencing and compared isolates from the TCV intervention arm to the MenA control arm with regard to (i) S. Typhi lineage distribution, (ii) AMR profile, (iii) mutations in genes associated with Vi capsule biosynthesis and expression and (iv) phylogenetic population structure.Results. We obtained high-quality genome sequences for 136 S. Typhi isolates (24 from the TCV arm, 112 from the MenA arm). Of these, 135 (99%) belonged to lineage L4.3.1.1.EA1. Isolates from the two arms were intermixed across multiple sub-clades. Nearly all isolates (135 out of 136) carried genes encoding resistance to ampicillin, cotrimoxazole and chloramphenicol. Non-synonymous mutations in the quinolone resistance determining region were identified in five isolates (three GyrA S83F; two GyrA S464F), and no statistically significant difference in prevalence of these mutations was observed between study arms (Fisher's exact test, P=0.25). Mutations in Vi capsule-associated genes were detected in 11 out of 112 (9%) MenA isolates and 1 out of 24 (4%) TCV isolates (Fisher's exact test, P=0.67). Fifteen MenA cases were hospitalized, two of whom had Vi-associated mutations. In one of these cases, the Vi mutation has previously been associated with increased virulence in a murine model; however, there was no significant association between tested Vi mutations and hospitalization (P>0.91).Conclusions. We identified no clinically meaningful genomic differences between S. Typhi isolates from participants vaccinated with TCV or MenA, and no Vi-negative S. Typhi were detected. These findings suggest no detectable short-term evolutionary impact of TCV on circulating S. Typhi populations in this Phase 3 trial. However, given the limited follow-up period and S. Typhi's relatively slow substitution rate, continued genomic surveillance in this population after national TCV introduction in 2023 is essential to detect evolutionary responses to vaccine pressure.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1.Key genes involved in Vi capsule synthesis included in the analysis.
非 KM Figure
Fig. 2.Maximum-likelihood phylogeny of 136 Phase 3 trial isolates contextualized with 302 previously sequenced S . Typhi isolates from Blantyre (innermost ring). The middle ring depicts the overall lineage distribution for both the trial and non-trial isolates. The outer ring shows the lineage distribution stratified by vaccine arm for the trial isolates.
非 KM Figure
Fig. 3.Temporal distribution of blood-culture–confirmed typhoid cases among trial isolates, stratified by vaccine group and presence of mutations within the Vi region. The x-axis represents the month of isolate collection, while the y-axis indicates the number of isolates obtained in each month. Bars are coloured according to four categories: TCV no mutation, TCV with mutation, MenA no mutation and MenA with mutation. ‘TCV’ denotes isolates recovered from participants who received the TCV, whereas ‘MenA’ denotes isolates from participants who received the meningococcal A conjugate vaccine, which served as the control vaccine in the trial. The ‘with mutation’ categories represent isolates in which mutations affecting the Vi region were identified, while the ‘no mutation’ categories represent isolates lacking detectable mutations in this region.
非 KM Figure
Fig. 4.Association between previously reported virulence-enhancing Vi-capsule SNPs and hospitalisation among MenA cases. Fisher’s exact test: P >0.91.
非 KM Figure